| Date | Title | | | 05/17/13 | Thoratec Announces FDA Approval Of HeartMate II® Pocket Controller™| PLEASANTON, Calif., May 17, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market the HeartMate II® Pocket Controller™, the small, smart, safe face of the HeartMate II LVAD System.
"In offering HeartMate II LVAD patients our next-generation Pocket Controller device, we a... |
|  | | 05/14/13 | Thoratec Presentation At Bank of America Merrill Lynch 2013 Health Care Conference To Be Webcast| PLEASANTON, Calif., May 14, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Bank of America Merrill Lynch 2013 Health Care Conference on Thursday, May 16.
Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 10:40 a.m., Pacific Daylight Time (1:40 p.m., Eastern Dayl... |
| | | 05/02/13 | Thoratec® Reports First Quarter 2013 Results| - Revenue of $117.7 million for the first quarter of 2013
- GAAP Net Income per Diluted Share of $0.31, and Non-GAAP Net Income per Diluted Share of $0.41
- Company reaffirms full-year 2013 guidance for revenue and earnings per share
PLEASANTON, Calif., May 2, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported its financial results for the first quar... |
| | | 04/22/13 | Thoratec Schedules First Quarter Conference Call, Webcast| PLEASANTON, Calif., April 22, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the first quarter of fiscal year 2013 on Thursday, May 2.
The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Daylight Time (4:30... |
| | | 03/19/13 | Meet Ms. Joe Ann Bivins, The World's Longest-Supported Recipient Of A Single Heart Assist Device| Implanted at University of Michigan Cardiovascular Center, Joe Ann's Heart has been Supported with the HeartMate II® Left Ventricular Assist Device since July 2005
PLEASANTON, Calif. and ANN ARBOR, Mich., March 19, 2013 /PRNewswire/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, and the University of Michigan Cardiovascular Center, a leader in cardiac care, today announced a maj... |
| | | 03/18/13 | Thoratec Announces the First Human Use of HeartMate PHP™|
PLEASANTON, Calif., March 18, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support, and restore failing hearts, announced today that it has successfully completed the first human use of HeartMate PHP (Percutaneous Heart Pump). The first PHP patient was supported for over 60 minutes during a high-risk percutaneous coronary intervention (HR PCI). The patient was hemodynamically stable during the p... |
| | | 03/11/13 | Thoratec Presentation At Barclays Global Healthcare Conference To Be Webcast|
PLEASANTON, Calif., March 11, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Barclays Global Healthcare Conference on Thursday, March 14.
Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 8:00 a.m., Eastern Daylight Time (5:00 a.m., Pacific Daylight Time).
... |
| | | 02/11/13 | Thoratec Presentation at Leerink Swann Global Healthcare Conference to Be Webcast|
PLEASANTON, Calif., Feb. 11, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Leerink Swann 2013 Global Healthcare Conference on Thursday, February 14.
Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 9:00 a.m., Eastern Standard Time (6:00 a.m., Pacific Standar... |
| | | 02/05/13 | Thoratec® Reports Fourth Quarter And Full Year Fiscal 2012 Financial Results| - Revenue of $128.5 million for the fourth quarter, an increase of 17% year-over-year, and $491.7 million for the full year, an increase of 16%
- HeartMate II® worldwide unit growth of 20% for the fourth quarter and 23% for fiscal year 2012
- GAAP Net Loss per Diluted Share of $0.25 for the fourth quarter, driven by PVAD™ and IVAD™ intangible asset write-down, and Net Income per Diluted Share of $0.94 for the full year
- Non-GAAP Net Income per Diluted Share of $0.38 for the fourth quar... |
| | | 01/28/13 | Thoratec Schedules Fourth Quarter Conference Call, Webcast|
PLEASANTON, Calif., Jan. 28, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for fiscal year 2012 on Tuesday, February 5.
The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Standard Time (4:30 p.m., Eastern S... |
| | | 01/07/13 | Thoratec Announces FDA Approval To Commence REVIVE-IT Study Utilizing HeartMate II®|
PLEASANTON, Calif., Jan. 7, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, today announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) to commence the REVIVE-IT study utilizing the HeartMate II® Left Ventricular Assist System.
REVIVE-IT (Randomized Evaluation of VAD InterVEntion before Inotropic The... |
| | | 01/03/13 | Thoratec Presentation At J.P. Morgan Healthcare Conference To Be Webcast|
PLEASANTON, Calif., Jan. 3, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the 31st Annual J.P. Morgan Healthcare Conference on Monday, January 7.
Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at 8:00 a.m., Pacific Standard Time (11:00 a.m., Eastern Standar... |
| |
|
